Ashvattha Therapeutics Announces $50 Million Financing Extension and Interim Phase 2 Ophthalmology Trial Results
Ashvattha receives additional financing up to $50 million with new lead investor Tribe Capital and existing investors led by Natural Capital Ashvattha’s at-home monthly subcutaneously-administered HDT (hydroxyl dendrimer therapeutic) for neovascular (wet) age-related macular degeneration (wet AMD) and diabetic macula edema (DME) demonstrated substantial reduction in treatment burden Interim Phase 2 trial results to be … Read more